Business
Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-built to strengthen medication impact through precision behavioral support at scale.
About this update from Dariohealth Corp.
[{"type":"text","content":"As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"Given GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in higher ROI ","length":229,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, March 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-built to strengthen medication impact through precision behavioral support at scale.","length":385,"tagName":"p"},{"type":"image","alt":"DarioHealth Logo","displaySize":"","headline":null,"caption":"DarioHealth Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":343,"url":"https://media.zenfs.com/en/prnewswire.com/c5f5995e168cf74689513b45bd90d485"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jC9OmKRCZYHTdykGPv3d_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c5f5995e168cf74689513b45bd90d485","width":400,"height":343}}},{"type":"text","content":"As oral GLP-1 therapies enter the market, data suggest they deliver slightly more modest weight and glycemic outcomes compared to injectable formulations. That dynamic elevates the importance of the surrounding behavioral infrastructure. Success ultimately depends on daily execution – timing, fasting windows, food decisions, symptom management and persistence through adjustment periods.","length":394,"tagName":"p"},{"type":"text","content":"Dario's book of business data shows that 79% of members engage in weight management within its integrated multi-condition platform. As a result, the Company has an extensive population benefiting from the solution's structured reinforcement.","length":249,"tagName":"p"},{"type":"text","content":"Dario's deep experience and data around weight management is a critical asset, as GLP-1 medi...